GO
Loading...

Novartis AG

More

  • European equities dip as healthcare stocks weaken Tuesday, 2 Sep 2014 | 10:16 AM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- European shares slipped on Tuesday as major healthcare stocks fell after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer. A 1.8 percent fall at AstraZeneca took the most points off the index.

  • BARCELONA, Sept 2- Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Strict British takeover rules limit what Soriot and other players can say about Pfizer's abortive attempt to buy AstraZeneca and the possibility of a resumption of talks.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares edged higher to close near a recent one-month peak on Monday, with merger and acquisition speculation about British broadcaster ITV helping media stocks and Novartis leading drugmakers.

  • European shares close flat to lower after PMI data Monday, 1 Sep 2014 | 11:45 AM ET

    European shares closed flat to lower on Monday as investors weighed worse-than-expected manufacturing data against tensions in Ukraine.

  • European shares tick higher, drugmakers advance Monday, 1 Sep 2014 | 11:17 AM ET

    *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares traded near a recent one-month peak on Monday, with merger and acquisition speculation about British broadcaster ITV helping media stocks and Novartis leading drugmakers. Novartis, up 4.7 percent, was the top gainer on the FTSEurofirst 300 index.

  • *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares edged higher to trade near a recent one-month peak on Monday, with mergers and acquisitions speculation surrounding British broadcaster ITV helping media stocks and Novartis leading drugmakers.

  • *Novartis sees margins on LCZ696 better than for Diovan. BARCELONA, Sept 1- Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease.

  • *FTSEurofirst 300 up 0.1, Euro STOXX 50 flat. LONDON, Sept 1- European shares kicked off September on a flat note as investors weighed mergers and acquisitions speculation and expectations of new monetary largesse in Europe against tensions in Ukraine and weak economic data out of China.

  • Shares of United Therapeutics closed up $26.14 at $117.83 on the Nasdaq, boosting the company's market value by about $1.24 billion to $5.57 billion.

  • In afternoon trading, United Therapeutics' shares were up $24.56, or 26.8 percent, at $116.25, after earlier rising as much as 28.7 percent to a record $118.00.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Hospira filed a lawsuit in U.S. District Court in Maryland on Tuesday asking for a temporary restraining order against the FDA, saying the agency's decision to allow generic Precedex went against its own rules.

  • *Novartis move adds to Big Pharma retreat from antibiotics R&D. ZURICH, Aug 20- Novartis has signed a licensing deal to hand over its experimental tuberculosis drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.

  • US labs on standby to start work on Ebola drug Sunday, 10 Aug 2014 | 6:02 AM ET
    A nurse wears protective clothing as he demonstrates the facilities in place at the Royal Free Hospital in north London on August 6, 2014, in preparation for a patient testing positive for the Ebola virus.

    All three U.S. laboratories established to fight major public health threats say they are standing by to scale up a treatment for Ebola.

  • NEW YORK/ WASHINGTON, Aug 9- All three U.S. facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.

  • NEW YORK,- A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

  • NEW YORK, Aug 7- A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

  • SAN FRANCISCO, Aug 5- The Netherlands' Royal Philips and IT consultancy Accenture are developing software to help people with neurodegenerative diseases like amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease, live more independently. Accenture and Philips jointly developed the software that connects the various technologies.